ArQule Investor Wants More Detail On $2.7B Merck Sale
An ArQule Inc. investor filed a proposed class action in Delaware federal court Thursday asserting stockholders need more information about Merck's $2.7 billion acquisition of the cancer-focused biopharmaceutical company to make...To view the full article, register now.
Already a subscriber? Click here to view full article